GSK Inks £2.075 Billion Deal with ABL Bio to Develop Innovative Therapies for Neurodegenerative Diseases Using Grabody-B Platform

Key Areas of Cooperation

• Technology Platform:GSK to Leverage ABL Bio's Blood-Brain Barrier (BBB) Shuttle Platform Grabody-B for Developing Innovative Drugs to Treat Neurodegenerative Diseases.
  

• Drug Development: This agreement aims to develop multiple therapeutic modalities, including antibodies, polynucleotides or oligonucleotides (such as siRNA and ASO), targeting various pathways to address the significant unmet medical needs of patients with neurodegenerative diseases.

• Division of Labor: ABL Bio is responsibleTransfer Grabody-B related technologies and proprietary technologies, with GSK leading preclinical development, manufacturing, and commercialization.

• Financial Terms：According to the agreement,ABL BioWill receive a total of up to£77 million upfront and near-term milestone payments。Overall, ABL Bio is qualifiedSecure up to £2.075 billion across multiple potential projectsMilestone payments for research and development, regulatory, and commercialization.
  

This collaboration will further solidify ABL Bio's leading position in the field of neurodegenerative diseases and expand the application scenarios of Grabody-B technology.

About ABL Bio

ABL Bio focuses on the development of the bispecific antibody platform "Grabody" and has 7 clinical pipelines (such as ABL301, ABL001, etc.) progressing in multiple countries including China, the U.S., and South Korea. Among them:

ABL001 (tovecimig): Granted FDA Fast Track Designation;

ABL111（givastomig）：Collaboration with I-MabIn 2025, the Phase Ib data for the triple therapy combining nivolumab and chemotherapy will be released;

In addition, ABL Bio is continuously researching and developing several other candidate products, including early-stage research on bispecific antibody-drug conjugates (ADCs).

End

---

Statement:All articles published on this official account (including original and reprinted articles) are intended to convey more information, with sources and authors clearly indicated. This official account welcomes sharing in friend circles or large groups.Reproduction in any form without the authorization of the media or organization is prohibited.。

Reprint/Business/Contribution| Contact WeChat15618157102（sum_Gmi）

Business Cooperation

Call for Papers

Click to learn more

Previous Review

1	Closure, Bankruptcy, Layoffs | The Shadow over Biopharmaceutical Companies in 2024
2	The World's First Semaglutide Chewable Soft Candy Launched!
3	China's First Male HPV Vaccine Approved for Marketing!